Aptinyx to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, March 24, 2021
Aptinyx Inc. (Nasdaq: APTX) will host a conference call and live webcast on March 24, 2021, at 5:00 p.m. ET to report its fourth-quarter and full-year 2020 financial results. The call will also discuss recent business highlights. Interested participants can join by calling (833) 772-0394 domestically or (236) 738-2205 internationally, using conference ID 4846816. A replay will be available for 30 days on Aptinyx’s website. The company focuses on developing therapies for brain and nervous system disorders and has three product candidates in clinical development.
- Aptinyx has three product candidates in clinical development targeting brain disorders.
- Company is advancing a proprietary discovery platform generating a diverse pipeline of NMDA receptor modulators.
- No specific financial metrics or performance outcomes are mentioned in the upcoming call.
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Wednesday, March 24, 2021 at 5:00 p.m. ET to report fourth quarter and full year 2020 financial results and discuss recent business highlights.
To access the live conference call, please dial (833) 772-0394 (domestic) or (236) 738-2205 (international) and refer to conference ID 4846816. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx’s website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx’s website for 30 days following the event.
About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson’s disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.
Source: Aptinyx Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005042/en/
FAQ
What financial results will Aptinyx report on March 24, 2021?
How can I access the Aptinyx conference call?
What is Aptinyx developing?
Will a replay of the Aptinyx conference call be available?
